To Evaluate the Safety, Pharmacokinetic and Pharmacodynamics of JW0061 in Healthy Volunteers
A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Clinical Trial to Evaluate the Safety, Pharmacokinetic and Pharmadynamics of JW0061 Following Topical Application in Korean and Caucasians Healthy Adults
JW Pharmaceutical
104 participants
Apr 13, 2026
INTERVENTIONAL
Conditions
Summary
This clinical study is a phase 1, randomized, double-blind, placebo-controlled, dose escalation clinical trial to evaluate the safety, pharmacokinetic and pharmacodynamics of JW0061 following topical application in Korean and Caucasians healthy adults.
Eligibility
Inclusion Criteria3
- Body weight between 50.0 kg and 90.0 kg, and BMI between 18.5 and 29.9 kg/m².
- Determined to be healthy and eligible by the investigator based on medical history, physical examination, and clinical laboratory tests.
- Capable of providing written informed consent and willing to comply with all study requirements and restrictions.
Exclusion Criteria3
- Presence of clinically significant scalp conditions that may interfere with safety assessments.
- History of malignancy within 5 years prior to screening.
- History of hypersensitivity or allergy to the study drug or its components.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Single ascending doses
Multiple ascending doses
Matching placebo for JW0061
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07514780